Peroxiredoxin 3 Inhibitors and Methods of Use for Treating Cancer
Summary
USPTO published patent application US20260109695A1 disclosing peroxiredoxin 3 (PRX3) inhibitor compounds of Formula (I) and methods of use for treating cancer. The application, filed August 25, 2023, names three inventors: W. Todd Lowther, Terrence L. Smalley Jr., and Kimberly J. Nelson. The CPC classifications span C07D (heterocyclic compounds) with therapeutic applications in cancer treatment (A61P 35/00).
“Provided according to some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt thereof.”
About this source
USPTO classification C07D covers heterocyclic organic compounds: the chemical core of most small-molecule drugs, including kinase inhibitors, GLP-1 receptor agonists, antibiotics, antivirals, and CNS therapies. Every newly published application in C07D lands in this feed, around 160 a month. Applications publish 18 months after filing, so this feed reveals what medicinal chemistry groups at Pfizer, Novartis, Roche, Shionogi, and others were synthesizing in the prior year and a half. Watch this if you run a medicinal chemistry program, file patent clearance for new drug candidates, scout competitor pipelines before clinical readouts, or track heterocyclic innovation across therapeutic areas.
What changed
USPTO published patent application US20260109695A1 for peroxiredoxin 3 (PRX3) inhibitor compounds and pharmaceutical compositions for treating cancer. The application discloses Formula (I) compounds, pharmaceutical formulations for oral or parenteral administration, and methods comprising administering a therapeutically effective amount to inhibit PRX3 and treat cancer. The filing date is August 25, 2023, with application number 19106395.
Affected parties include pharmaceutical companies developing oncology therapeutics, cancer researchers, and drug manufacturers. Patent applications do not create immediate compliance obligations but establish priority rights and signal active development in the PRX3 target space for cancer therapy. Parties interested in this technology area should monitor prosecution status and consider freedom-to-operate analysis.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER
Application US20260109695A1 Kind: A1 Apr 23, 2026
Inventors
W. Todd LOWTHER, Terrence L. Smalley, JR., Kimberly J. Nelson
Abstract
Provided according to some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions formulated for oral or parenteral administration comprising the same and methods of use for treating cancer and inhibiting PRX3 comprising administering to the subject a therapeutically effective amount of a compound are also provided.
CPC Classifications
C07D 417/14 A61K 31/282 A61K 31/337 A61K 31/454 A61K 31/4545 A61K 31/69 A61K 31/704 A61K 45/06 A61P 35/00 C07D 417/04
Filing Date
2023-08-25
Application No.
19106395
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.